CORRESP Filing
Liminatus Pharma, Inc.
Date: Feb. 11, 2026 · CIK: 0001971387 · Accession: 0001104659-26-013331
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293364
Letter
Liminatus Pharma, Inc.
12611 Hiddencreek Way, Unit C
Cerritos, CA 90703
February 11, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Washington, D.C. 20549
Attention: Mr. Daniel Crawford
RE: Liminatus Pharma, Inc. (the "Company")
Registration Statement on Form S-1 (File No. 333-293364) (the "Registration Statement") Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the "Act"), the Company requests that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the Registration Statement to become effective on February 13, 2026 at 9:00 a.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Very truly yours,
Liminatus Pharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm Liminatus Pharma, Inc. 12611 Hiddencreek Way, Unit C Cerritos, CA 90703 February 11, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Mr. Daniel Crawford RE: Liminatus Pharma, Inc. (the "Company") Registration Statement on Form S-1 (File No. 333-293364) (the "Registration Statement") Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the "Act"), the Company requests that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the Registration Statement to become effective on February 13, 2026 at 9:00 a.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Very truly yours, Liminatus Pharma, Inc. By: /s/ Chris Kim Name: Chris Kim Title: Chief Executive Officer cc: Giovanni Caruso, Loeb & Loeb LLP